The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway
Context: Lutein (LU) is a major carotenoid with various pharmacological activities including anti-inflammatory, antioxidant and anti-apoptosis. Objective: The cardioprotective efficacy of LU was determined by evaluating the biochemical and histopathological changes in isoproterenol (ISO) induced myo...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Pharmaceutical Biology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/13880209.2019.1649436 |
id |
doaj-ff9d24e775c94fb394d567e9e19f48d2 |
---|---|
record_format |
Article |
spelling |
doaj-ff9d24e775c94fb394d567e9e19f48d22020-11-25T03:08:26ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162019-01-0157152953510.1080/13880209.2019.16494361649436The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathwayBo Ouyang0Zili Li1Xiongying Ji2Jiangwei Huang3Hengsheng Zhang4Changrong Jiang5Affiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaContext: Lutein (LU) is a major carotenoid with various pharmacological activities including anti-inflammatory, antioxidant and anti-apoptosis. Objective: The cardioprotective efficacy of LU was determined by evaluating the biochemical and histopathological changes in isoproterenol (ISO) induced myocardial infarction (MI) rat model. Materials and methods: Healthy male albino rats (n = 40) were segregated into 4 equal groups. Group I (control) rats were administered with olive oil, Group II (LU) rats were orally pre-treated with only 40 mg of LU for 28 days, Group III (MI induced) rats were injected (subcutaneously; s.c) with 85 mg/kg of ISO for 2 consecutive days, whereas Group IV (LU + ISO) rats were pre-treated with 40 mg of LU for 28 days before ISO induction. Results: ISO-induced group showed increased infarct size and cardiac/inflammatory/apoptotic markers. However, pre-treatment with LU (28 days) considerably reduced (p < 0.01) the infarct size (14%), lipid peroxidation product (MDA;42%), cardiac markers [(lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB), cardiac troponin T (cTn T)], inflammatory markers [IL-1β, IL-6, tumour necrosis factor alpha (TNF-α), nuclear factor kappa B p65 subunit (NF-κB p65)] and apoptotic markers (caspase-3 and -9). Also, LU significantly improved (p < 0.01) the antioxidants [catalase (CAT), superoxide dismutase (SOD)] as well as markedly upregulated (p < 0.01) the protein expression of HO-1 and Nrf2. Moreover, LU considerably reversed all the histopathological changes and thus exhibits its cardioprotective activity. Conclusion: LU exhibits potent cardioprotective activity against ISO-induced cardiotoxicity and might be recommended with standard cardioprotective agents for treating various MI-related complications.http://dx.doi.org/10.1080/13880209.2019.1649436myocardial infarctioninfarct sizecardioprotectivecardiac markers |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bo Ouyang Zili Li Xiongying Ji Jiangwei Huang Hengsheng Zhang Changrong Jiang |
spellingShingle |
Bo Ouyang Zili Li Xiongying Ji Jiangwei Huang Hengsheng Zhang Changrong Jiang The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway Pharmaceutical Biology myocardial infarction infarct size cardioprotective cardiac markers |
author_facet |
Bo Ouyang Zili Li Xiongying Ji Jiangwei Huang Hengsheng Zhang Changrong Jiang |
author_sort |
Bo Ouyang |
title |
The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway |
title_short |
The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway |
title_full |
The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway |
title_fullStr |
The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway |
title_full_unstemmed |
The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway |
title_sort |
protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating nrf2/ho-1 signalling pathway |
publisher |
Taylor & Francis Group |
series |
Pharmaceutical Biology |
issn |
1388-0209 1744-5116 |
publishDate |
2019-01-01 |
description |
Context: Lutein (LU) is a major carotenoid with various pharmacological activities including anti-inflammatory, antioxidant and anti-apoptosis. Objective: The cardioprotective efficacy of LU was determined by evaluating the biochemical and histopathological changes in isoproterenol (ISO) induced myocardial infarction (MI) rat model. Materials and methods: Healthy male albino rats (n = 40) were segregated into 4 equal groups. Group I (control) rats were administered with olive oil, Group II (LU) rats were orally pre-treated with only 40 mg of LU for 28 days, Group III (MI induced) rats were injected (subcutaneously; s.c) with 85 mg/kg of ISO for 2 consecutive days, whereas Group IV (LU + ISO) rats were pre-treated with 40 mg of LU for 28 days before ISO induction. Results: ISO-induced group showed increased infarct size and cardiac/inflammatory/apoptotic markers. However, pre-treatment with LU (28 days) considerably reduced (p < 0.01) the infarct size (14%), lipid peroxidation product (MDA;42%), cardiac markers [(lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB), cardiac troponin T (cTn T)], inflammatory markers [IL-1β, IL-6, tumour necrosis factor alpha (TNF-α), nuclear factor kappa B p65 subunit (NF-κB p65)] and apoptotic markers (caspase-3 and -9). Also, LU significantly improved (p < 0.01) the antioxidants [catalase (CAT), superoxide dismutase (SOD)] as well as markedly upregulated (p < 0.01) the protein expression of HO-1 and Nrf2. Moreover, LU considerably reversed all the histopathological changes and thus exhibits its cardioprotective activity. Conclusion: LU exhibits potent cardioprotective activity against ISO-induced cardiotoxicity and might be recommended with standard cardioprotective agents for treating various MI-related complications. |
topic |
myocardial infarction infarct size cardioprotective cardiac markers |
url |
http://dx.doi.org/10.1080/13880209.2019.1649436 |
work_keys_str_mv |
AT boouyang theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT zilili theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT xiongyingji theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT jiangweihuang theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT hengshengzhang theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT changrongjiang theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT boouyang protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT zilili protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT xiongyingji protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT jiangweihuang protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT hengshengzhang protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway AT changrongjiang protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway |
_version_ |
1715295783093272576 |